Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Pulmonary Hypertension
NCT06612086Phase 1Not yet recruiting
- Sponsor
- Assiut University
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dapagliflozin in pulmonary hypertension (PH), sponsored by Assiut University. Primary endpoint: Right Ventricle Systolic Function by Speckle Tracking Echocardiography (RV Strain) at 6 months. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT06612086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612086.